LES Foundation | LESI | Print Page | Contact Us | Sign In | Join
The Future is Now: Dealing in a Transformed Healthcare Environment
Tell a Friend About This EventTell a Friend

NJ Sept Event

When: Tuesday, September 27, 2016
6:00-9:00 p.m.
Where: Dolce Basking Ridge
300 North Maple Avenue
Basking Ridge, New Jersey  07920
United States
Contact: Dolly Koltchev, PhD

Online registration is closed.
« Go to Upcoming Event List  

The Future is Now: Dealing in a Transformed Healthcare Environment

A Special Tribute to Tom Picone, LES Past-President and Member, NJ Chapter

Tuesday, September 27, 2016
6:00-9:00 p.m.

6:00 - 7:00 p.m. -- Networking Reception
7:00 - 7:15 p.m. -- A Tribute to Tom Picone, Pamela Demain, Merck
7:15 - 8:30 p.m. -- Presentation, Ed Saltzman, Defined Health
8:30 - 9:00 p.m. -- Q&A, Coffee & Desserts

Dress Code: Business or Business Casual 


Early Registration (By Sept. 20)
After Sept. 20:
LES Member: $65.00
LES Non-Member: $75.00
LES Student Member: $40.00
LES Member: $75.00
LES Non-Member: $85.00
LES Student Member: $50.00

 Professionals in transition are welcome to contact Dolly Koltchev (above) to discuss a discounted rate.

This meeting is dedicated to Tom Picone, who worked over 30 years in the pharmaceutical industry, starting in R&D and then moving to Business Development and Licensing.  A hallmark of his career included serving as a Trustee of LES for over ten years and President of LES from 2007-08.  His work at LES was recognized by the Society by awarding him with the Frank Barnes' Memorial Award in 2010. 

Ed Saltzman
President and Founder
Defined Health

Ed Saltzman, the 2016 Frank Barnes’ nominee, will present an overview of the current dealmaking trends in BioPharma. The long term symbiosis between large Pharma and Biotech has been driven by two seemingly inexhaustible factors: Pharma’s quest for innovation and Biotech’s thirst for non-dilutive cash. Despite some increased complexity in deal structure and temporary fluctuation in market conditions favoring either buyers or sellers, this relationship has existed for so long that it is easy to take its permanence for granted.

Seemingly suddenly, however, a host of forces in science, technology, finance and the market environment are poised to act synergistically to cause permanent disruption to this long-standing relationship. Among these: a number of regenerative medicine platforms and cell and gene therapies nearing or passing PoC, major breakthroughs in personalized medicine via enormous advances in sequencing, as well as an increasing focus on treating specialist managed and rare diseases.

Unfortunately, the BioPharma business model appears stuck in a “time capsule” created in the days when global scale and massive development and commercial organizations were synonymous with “Big Pharma” and the roles of “R&D,” “Commercial,” and "BD" were comparatively well-delineated. Concepts for how value inflection is achieved in Biotech appear to be frozen in a similar window of time, despite some advancement in thinking around replacing traditional proof of concept with Proof of Relevance. Perhaps most threatened with disruption by an increasingly powerful and consolidated group of stakeholders are today’s still surviving views that price premiums are a well-deserved reward for every new “breakthrough” or rare disease therapy.

This presentation will address the convergence of these disruptive forces and suggest ways the BioPharma business model may need to evolve in order to respond to them.